For the roughly 3–7% of non-small-cell lung cancer patients whose tumors carry an ALK gene rearrangement, surgery remains the primary curative strategy — but relapse rates after resection have historically been substantial. Whether next-generation ALK inhibitors can meaningfully extend disease-free survival in the adjuvant setting is one of the most consequential open questions in thoracic oncology, and this trial begins to answer it.
Published in the New England Journal of Medicine, this phase III randomized trial evaluated ensartinib — a potent, brain-penetrant second-generation ALK tyrosine kinase inhibitor — as adjuvant therapy following complete resection in patients with stage IB–IIIA ALK-positive NSCLC. The trial enrolled patients across multiple centers and compared ensartinib against a control arm, measuring disease-free survival as the primary endpoint. Results demonstrated a statistically significant improvement in disease-free survival for patients receiving ensartinib, with particular relevance given the drug's known activity against central nervous system metastases, which represent a common and devastating relapse site in ALK-positive disease.
This finding carries considerable weight when placed in the broader context of adjuvant targeted therapy for NSCLC. The first-generation ALK inhibitor crizotinib showed modest adjuvant benefit, while alectinib — a competing second-generation agent — established a strong precedent with its ALINA trial results demonstrating dramatic disease-free survival gains. Ensartinib's trial now adds a second agent to this class with demonstrated adjuvant efficacy, potentially expanding treatment options and creating a competitive landscape for ALK-positive patients post-surgery. The CNS penetration advantage of ensartinib is clinically meaningful since brain recurrence drives significant morbidity in this population. Key limitations include that overall survival data remain immature — standard for adjuvant oncology trials — and long-term tolerability data will matter for a population receiving extended oral therapy. This is a confirmatory and clinically significant result that reinforces adjuvant ALK inhibition as a standard-of-care paradigm rather than an experimental approach.